<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:regn="http://regeneron.com/20221219">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_regn_regeneron.com_20221219 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20221219_20221219 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="regn-20221219.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-12-19to2022-12-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-19</xbrli:startDate>
        <xbrli:endDate>2022-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20221219__20221219_zBScHm9L7rN6"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
December 20, 2022 (<span id="xdx_901_edei--DocumentPeriodEndDate_c20221219__20221219_zJSb06p15vQd"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 19, 2022</ix:nonNumeric></span>)</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20221219__20221219_zzSNcU0KaVGi"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20221219__20221219_zG5Iu1gKISCk"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(State or other
jurisdiction of incorporation)</b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 51%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20221219__20221219_zdQ2OcYGXif6"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 48%"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20221219__20221219_zoGZjcQlRymf"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(Commission</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>File Number)</b></span></p></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(I.R.S.
                                    Employer</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Identification
        No.)</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td></tr>
<tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20221219__20221219_zb7kX3gP7S1l"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20221219__20221219_zSOOjLSMnvQ9"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20221219__20221219_zOiUbX310Pze"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: bottom; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20221219__20221219_z1uRN3UWBVGb"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_90B_edei--CityAreaCode_c20221219__20221219_z61MApJmbYLg"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20221219__20221219_z0CUZKipUA0f"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20221219__20221219_zyhr9FIUFhk6"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20221219__20221219_zhFpqVSMK3n5"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20221219__20221219_zoVSmawlheO5"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20221219__20221219_zwAV8eqswWpi"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font-size: 10pt; border-image: none; width: 42%; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><i><span style="text-decoration: underline">Title
    of each class</span></i></span></td>
    <td style="font-size: 10pt; width: 20%; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><i><span style="text-decoration: underline">Trading
    Symbol(s)</span></i></span></td>
    <td style="font-size: 10pt; width: 38%; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><i><span style="text-decoration: underline">Name
    of each exchange on which <br />
    registered</span></i></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20221219__20221219_z9SOSBd0gDRi"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:Security12bTitle">Common stock &#8211; par value $.001 per share</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20221219__20221219_z3ydrbapctpj"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20221219__20221219_zeGcAUIr0iRh"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20221219__20221219_zN4AV4mJwve"><ix:nonNumeric contextRef="From2022-12-19to2022-12-19" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><b>Item 1.01.</b></td><td><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
December 19, 2022 (the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;), Regeneron Pharmaceuticals, Inc. (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221; or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
entered into a credit agreement (the &#8220;<span style="text-decoration: underline">Credit Agreement</span>&#8221;) by and among the Company, as a borrower and guarantor; </span>certain
direct subsidiaries of the Company, as the initial subsidiary borrowers; the lenders and issuing banks from time to time party thereto;
and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Credit Agreement provides for a $750 million
senior unsecured five-year revolving credit facility (with a $25 million sublimit for swingline borrowings and a $50 million sublimit
for letters of credit) (the &#8220;<span style="text-decoration: underline">Credit Facility</span>&#8221;) and replaces the Company&#8217;s previously existing $750 million revolving
credit facility, which was contemporaneously terminated as described in Item 1.02 below. The loans under the Credit Facility have a variable
interest rate based on either the Secured Overnight Financing Rate-based rate or the alternate base rate (or other applicable rate with
respect to non-dollar borrowings), plus an applicable margin that varies with the Company&#8217;s debt rating and total leverage ratio.
The Credit Agreement includes an option for the Company to elect to increase the commitments under the Credit Facility and/or to enter
into one or more tranches of term loans in the aggregate principal amount of up to $500 million, subject to the consent of the lenders
providing the additional commitments or term loans, as applicable, and certain other conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As set forth in the Credit Agreement, the Company
has the option to amend the Credit Agreement to establish environmental, social, and governance targets which will be used to adjust pricing
under the Credit Facility, subject to parameters to be provided in the amended Credit Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The proceeds of the loans under the Credit Facility
may be used to finance the working capital needs, and for general corporate or other lawful purposes, of Regeneron and its subsidiaries.
The Company has guaranteed all obligations under the Credit Facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Credit Agreement contains operating covenants
and a maximum total leverage ratio financial covenant. Operating covenants include, among other things, limitations on (i) the incurrence
of indebtedness by the Company&#8217;s subsidiaries, (ii) liens on assets of the Company and its subsidiaries, and (iii) certain fundamental
changes and the disposition of assets by the Company and its subsidiaries. The Credit Agreement contains other customary covenants, representations
and warranties, and events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Credit Facility matures, and all amounts outstanding
thereunder will become due and payable in full, on December 19, 2027. The Credit Agreement includes an option for the Company to elect
to extend the maturity date of the Credit Facility, subject to the consent of the extending lenders and certain other conditions. Amounts
borrowed under the Credit Facility may be prepaid, and the commitments under the Credit Facility may be terminated, at any time without
premium or penalty. As of the date of this report, no borrowings were outstanding under the Credit Facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing summary of the Credit Agreement
is qualified in its entirety by the full text of the Credit Agreement, which is attached as Exhibit 10.1 hereto and is incorporated herein
by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><b>Item 1.02.</b></td><td><b>Termination of a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On the Closing Date, in connection with the entry
into the Credit Agreement as described in Item 1.01 above, the Company terminated its then-existing credit agreement, dated as of December
14, 2018, as amended prior to the Closing Date (the &#8220;<span style="text-decoration: underline">Prior Credit Agreement</span>&#8221;), by and among Regeneron, as a borrower
and guarantor; certain subsidiaries of Regeneron party thereto as subsidiary borrowers; the lenders and issuing banks from time to time
party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank. In connection with the termination
of the Prior Credit Agreement, all guarantees thereunder were terminated and released. No borrowings were outstanding under the Prior
Credit Agreement at the time of its termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><b>Item 2.03.</b></td><td><b>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. </b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On the Closing Date, the Company entered into
the Credit Agreement as described under Item 1.01 above. The description of the Credit Agreement set forth in Item 1.01 above is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><b>Item 9.01.</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 5%; padding-right: 0.8pt"><a href="tm2233051d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="vertical-align: bottom; width: 2%; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; width: 93%; padding-right: 0.8pt"><a href="tm2233051d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit Agreement, dated as of December 19, 2022, by and among Regeneron Pharmaceuticals, Inc., as a borrower and guarantor; certain direct subsidiaries of Regeneron Pharmaceuticals, Inc., as the initial subsidiary borrowers; the lenders and issuing banks party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank.*</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Certain schedules and exhibits have been omitted pursuant to Item
601(b)(2) of Regulation S-K. Regeneron hereby undertakes to furnish supplemental copies of any of the omitted schedules or exhibits to
the Securities and Exchange Commission upon request.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="width: 50%"><b>REGENERON PHARMACEUTICALS, INC.&#160; &#160;</b></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">/s/ Joseph J. LaRosa</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph J. LaRosa</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President, General Counsel and Secretary</span></td></tr>
  <tr>
    <td colspan="2">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 20, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
